Clinical Trials Logo

Solid Tumor, Unspecified, Adult clinical trials

View clinical trials related to Solid Tumor, Unspecified, Adult.

Filter by:

NCT ID: NCT06136065 Recruiting - Clinical trials for Solid Tumor, Unspecified, Adult

68 Gallium-Fibroblast Activating Protein Inhibitors-46 Positron Emission Tomography - Computerized Tomography for Molecular Assessment of Fibroblast Activation and Risk Assessment in Solid Tumors

FAPI
Start date: August 21, 2023
Phase: Phase 2
Study type: Interventional

Phase II, open label, single arm, single center, prospective diagnostic trial to evaluate the Fibroblast Activating Protein (FAP) positivity in patients with solid tumors

NCT ID: NCT05723640 Recruiting - Clinical trials for Solid Tumor, Unspecified, Adult

The Safety and Dosimetry Study of 177Lu-LNC1004 Injection

Start date: October 3, 2023
Phase: Phase 1
Study type: Interventional

This proposal is a phase I, open-label study of a 4-Dose Regimen of Escalating Doses of 177Lu-LNC1004 Injection in patients with recurrent or metastatic, fibroblast activation protein-positive solid tumors. In the clinical development, we aim to demonstrate the following: - 177Lu-LNC1004 Injection is safe and tolerable at therapeutic dose. - Determination of dose(s) to be used in the expansion phase. The treatment regimen will consist of a single dose intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles. The dose per cycle will be fixed for each patient and will be escalated in 4 different dose levels

NCT ID: NCT05695638 Recruiting - Clinical trials for Haematological Malignancy

Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment

Start date: July 1, 2020
Phase:
Study type: Observational [Patient Registry]

Proseq Cancer is a precision medicine program based on in-house whole exome sequencing (WES) and RNA sequencing. The approved protocol allows for biobanking, registration of clinical and laboratory data, and sharing of genomic data with the purpose of research, while fulfilling the Danish General Data Protection Regulation (GDPR) requirements. Patients are recruited from the North Denmark Region. Treatment can be offered on site if a targeted drug of a nationally approved indication is suggested by the national tumor board (NTB). If not, the patient may be treated in an available clinical protocol. If no approved drug or relevant protocol is available or feasible, treatment with a targeted drug used outside a clinical protocol is pursued.

NCT ID: NCT04976803 Completed - Clinical trials for Solid Tumor, Unspecified, Adult

Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein

ATM
Start date: May 28, 2021
Phase:
Study type: Observational

This study examines the correlation between ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.

NCT ID: NCT04942717 Recruiting - Solid Tumor Clinical Trials

Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values

Start date: June 18, 2021
Phase:
Study type: Observational

The purpose of this study is to translate and tailor for Latinx participants a program called Communicating with Oncology Nurses about Values from the Outset (CONVO). In CONVO, routine cancer care for each participant includes a discussion between the nurse and participant about the participant's health-related values.

NCT ID: NCT04932525 Recruiting - Clinical trials for Solid Tumor, Unspecified, Adult

Gustave Roussy Cancer Profiling

STING
Start date: May 10, 2021
Phase: Phase 1
Study type: Interventional

The objective of STING study is to perform high throughput molecular analysis (next generation sequencing +/- immunological profiling) to estimate the proportion of patients with cancer presenting at least one targetable genomic alteration.

NCT ID: NCT04643418 Recruiting - Clinical trials for Solid Tumor, Unspecified, Adult

Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors

Start date: March 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human (FIH), multicenter, open-label, uncontrolled, Phase 1/2a study with dose escalation in patients with advanced solid tumors (Part 1) and cohorts of up to 15 patients per selected indication (Part 2). The solid tumor types in Part 2 will be decided by the sponsor prior to the start of Part 2, but not be solely based on the efficacy results in Part 1.

NCT ID: NCT04577963 Active, not recruiting - Colorectal Cancer Clinical Trials

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Start date: August 9, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multi-center, non-randomized, Phase 1b/2 study to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with locally advanced or metastatic solid tumors. This study will be conducted in 2 parts; a Safety Lead-in Phase (Part 1) and a Dose Expansion Phase (Part 2). The Safety Lead-in Phase, open to any-comer solid tumors, will determine the RP2D. The RP2D will be administered to 3 cohorts of patients in the Dose Expansion Phase. - Cohort A: Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IO-treated) - Cohort B: Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IO-Naïve) - Cohort C: Advanced or Metastatic Endometrial Cancer (EC) (IO-Naïve) - Cohort D: Advanced or Metastatic Colorectal Cancer (mCRC) (IO-Naïve)

NCT ID: NCT04537936 Recruiting - Solid Tumor Clinical Trials

Psychotherapy Intervention for Latinos With Adv Cancer

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to adapt a counseling intervention called Meaning Centered Psychotherapy to make it culturally relevant for Latinos. Cancer affects patients and their loved ones. Latinos often experience greater challenges due to the cancer. However, few studies and interventions focus on Latinos. We are interested in understanding what affects Latino patients' quality of life, and how to improve it

NCT ID: NCT04443088 Recruiting - Cancer Clinical Trials

An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

KEYNOTE-E12
Start date: June 26, 2020
Phase: Phase 1
Study type: Interventional

Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed in adult patients with advanced solid tumors.